Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (otvorí nové okno)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Zdroj‎: Br J Haematol 2013;161(5):738-40.

Označenie‎: PubMed 23480574

Identifikátor digitálneho objektu‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (otvorí nové okno)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (otvorí nové okno)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Zdroj‎: Haematologica 2021;106(4):1148-57.

Označenie‎: PubMed 32499239

Identifikátor digitálneho objektu‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (otvorí nové okno)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (otvorí nové okno)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Zdroj‎: Cancer 2008;113(6):1338-43.

Označenie‎: PubMed 18629842

Identifikátor digitálneho objektu‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (otvorí nové okno)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (otvorí nové okno)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Zdroj‎: Transfusion 2012;52(4):739-41.

Označenie‎: PubMed 22082044

Identifikátor digitálneho objektu‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (otvorí nové okno)

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (otvorí nové okno)

Bhatia M, Davenport V, Cairo MS.

Zdroj‎: Leuk Lymphoma 2007;48(1):9-15.

Označenie‎: PubMed 17325843

Identifikátor digitálneho objektu‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 (otvorí nové okno)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (otvorí nové okno)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Zdroj‎: BMC Cancer 2013;13:121.

Označenie‎: PubMed 23497336

Identifikátor digitálneho objektu‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (otvorí nové okno)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (otvorí nové okno)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Zdroj‎: Pathol Oncol Res 2011;17(1):141-3.

Označenie‎: PubMed 20628840

Identifikátor digitálneho objektu‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (otvorí nové okno)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (otvorí nové okno)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Zdroj‎: J Neurooncol 2012;106(2):427-9.

Označenie‎: PubMed 21833801

Identifikátor digitálneho objektu‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (otvorí nové okno)

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (otvorí nové okno)

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

Zdroj‎: Lancet 2003;361(9354):275-80.

Označenie‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 (otvorí nové okno)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (otvorí nové okno)

Ford PA, Grant SJ, Mick R, Keck G.

Zdroj‎: J Clin Oncol 2015;33(15):1674-9.

Označenie‎: PubMed 25870085

Identifikátor digitálneho objektu‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (otvorí nové okno)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (otvorí nové okno)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Zdroj‎: Platelets. 2022 3;33(7):1024-1030.

Označenie‎: PubMed 35040375

Identifikátor digitálneho objektu‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (otvorí nové okno)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (otvorí nové okno)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Zdroj‎: Cancer 2014;120(12):1838-46.

Označenie‎: PubMed 24706489

Identifikátor digitálneho objektu‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (otvorí nové okno)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (otvorí nové okno)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Zdroj‎: Leuk Lymphoma 2013;54(2):321-8.

Označenie‎: PubMed 22906162

Identifikátor digitálneho objektu‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (otvorí nové okno)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (otvorí nové okno)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Zdroj‎: Platelets 2012;23(6):423-9.

Označenie‎: PubMed 22185370

Identifikátor digitálneho objektu‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (otvorí nové okno)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (otvorí nové okno)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Zdroj‎: Ann Hematol 2015;94(1):117-28.

Označenie‎: PubMed 25069650

Identifikátor digitálneho objektu‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (otvorí nové okno)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (otvorí nové okno)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Zdroj‎: J Hematol Oncol 2015;8:37.

Označenie‎: PubMed 25886818

Identifikátor digitálneho objektu‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (otvorí nové okno)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (otvorí nové okno)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Zdroj‎: J Clin Oncol 2010;28(3):437-44.

Označenie‎: PubMed 20008626

Identifikátor digitálneho objektu‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (otvorí nové okno)

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (otvorí nové okno)

Locantore-Ford P, Grant SJ, Keck G.

Zdroj‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 (otvorí nové okno)

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (otvorí nové okno)

Loo M, Beguin Y.

Zdroj‎: Blood 1999;93(10):3286-93.

Označenie‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 (otvorí nové okno)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (otvorí nové okno)

Miao J, Leblebjian H, Scullion B, Parnes A

Zdroj‎: Am J Hematol 2018;93(4):E86-E88.

Označenie‎: PubMed 29274130

Identifikátor digitálneho objektu‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (otvorí nové okno)

Pharmacological therapies to minimise platelet transfusion. (otvorí nové okno)

Norfolk DR, Seghatchian J.

Zdroj‎: Transfus Sci 2000;22(3):149-53.

Označenie‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 (otvorí nové okno)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (otvorí nové okno)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Zdroj‎: Support Care Cancer 2014;22(5):1217-22.

Označenie‎: PubMed 24414994

Identifikátor digitálneho objektu‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (otvorí nové okno)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (otvorí nové okno)

Pathak S, Roth M, Verma A, Steidl U.

Zdroj‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

Označenie‎: PubMed 24215532

Identifikátor digitálneho objektu‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (otvorí nové okno)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (otvorí nové okno)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Zdroj‎: Leuk Lymphoma. 2019;60(9):2324-7.

Označenie‎: PubMed 30773115

Identifikátor digitálneho objektu‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (otvorí nové okno)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (otvorí nové okno)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Zdroj‎: Lancet Haematol 2015;2(10):e417-26.

Označenie‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (otvorí nové okno)

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (otvorí nové okno)

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

Zdroj‎: Am J Blood Res 2013;3(3):260-4.

Označenie‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 (otvorí nové okno)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (otvorí nové okno)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Zdroj‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

Označenie‎: PubMed 26306064

Identifikátor digitálneho objektu‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (otvorí nové okno)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (otvorí nové okno)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Zdroj‎: Blood 2010;116(12):2127-33.

Označenie‎: PubMed 20530792

Identifikátor digitálneho objektu‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (otvorí nové okno)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (otvorí nové okno)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Zdroj‎: Blood 2012;120(2):386-94.

Označenie‎: PubMed 22627766

Identifikátor digitálneho objektu‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (otvorí nové okno)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (otvorí nové okno)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Zdroj‎: Cancer 2011;117(5):992-1000.

Označenie‎: PubMed 20945323

Identifikátor digitálneho objektu‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (otvorí nové okno)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (otvorí nové okno)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Zdroj‎: J Clin Oncol 2019;37(31):2892-8.

Označenie‎: PubMed 31545663

Identifikátor digitálneho objektu‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (otvorí nové okno)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (otvorí nové okno)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Zdroj‎: Blood 2000;95(9):2983-9.

Označenie‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (otvorí nové okno)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (otvorí nové okno)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Zdroj‎: Eur J Haematol 2014;93(5):439-45.

Označenie‎: PubMed 24853277

Identifikátor digitálneho objektu‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (otvorí nové okno)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (otvorí nové okno)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Zdroj‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

Označenie‎: PubMed 26785333

Identifikátor digitálneho objektu‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (otvorí nové okno)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (otvorí nové okno)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Zdroj‎: Ann Oncol 2005;16(1):139-45.

Označenie‎: PubMed 15598951

Identifikátor digitálneho objektu‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (otvorí nové okno)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (otvorí nové okno)

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

Zdroj‎: J Hematol Oncol 2012;5:71.

Označenie‎: PubMed 23190430

Identifikátor digitálneho objektu‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 (otvorí nové okno)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (otvorí nové okno)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Zdroj‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

Označenie‎: PubMed 35582038

Identifikátor digitálneho objektu‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (otvorí nové okno)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (otvorí nové okno)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Zdroj‎: Blood 2009;114(18):3899-908.

Označenie‎: PubMed 19710504

Identifikátor digitálneho objektu‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (otvorí nové okno)